Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Sanuwave Health ( (SNWV) ) is now available.
On September 25, 2025, Sanuwave Health, Inc. entered into a credit agreement with JPMorgan Chase Bank for a $23 million term loan and a $5 million revolving credit facility. This refinancing allowed Sanuwave to repay its previous debt facility with NH Expansion Credit Fund Holdings LP, marking a significant step in strengthening its financial position by reducing interest rates and overall debt load, thereby enhancing cash flow generation.
The most recent analyst rating on (SNWV) stock is a Hold with a $33.00 price target. To see the full list of analyst forecasts on Sanuwave Health stock, see the SNWV Stock Forecast page.
Spark’s Take on SNWV Stock
According to Spark, TipRanks’ AI Analyst, SNWV is a Neutral.
Sanuwave Health’s overall stock score is primarily impacted by its weak financial performance, characterized by negative equity and cash flow issues. Technical analysis indicates bearish momentum, and the valuation is poor due to a negative P/E ratio. While the earnings call provided some positive insights, the company’s financial instability remains a significant concern.
To see Spark’s full report on SNWV stock, click here.
More about Sanuwave Health
Sanuwave Health, Inc. is a leading provider of next-generation FDA-approved wound care products.
Average Trading Volume: 65,114
Technical Sentiment Signal: Buy
Current Market Cap: $307.8M
For detailed information about SNWV stock, go to TipRanks’ Stock Analysis page.